tipifarnib has been researched along with Hypoxia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdul-Salam, VB; Ahmetaj-Shala, B; Aldabbous, L; Dubois, OD; Duluc, L; Iannone, L; Mahomed, AS; Mitchell, J; Oliver, E; Storck, EM; Tate, EW; Wilkins, MR; Wojciak-Stothard, B; Zhao, L | 1 |
| Merkus, D; Schermuly, RT | 1 |
2 other study(ies) available for tipifarnib and Hypoxia
| Article | Year |
|---|---|
Tipifarnib prevents development of hypoxia-induced pulmonary hypertension.
Topics: Animals; Antihypertensive Agents; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Endothelial Cells; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Hypertension, Pulmonary; Hypoxia; Male; Mice, Inbred C57BL; Phenotype; Protein Prenylation; Proteomics; Pulmonary Artery; Quinolones; rhoB GTP-Binding Protein; Time Factors; Transfection; Vasoconstriction; Vasodilation | 2017 |
Farnesylation of RhoB: the cancer hypothesis of pulmonary hypertension revisited.
Topics: Humans; Hypertension, Pulmonary; Hypoxia; Neoplasms; Prenylation; Quinolones; rhoB GTP-Binding Protein | 2017 |